Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

thymic epithelial neoplasm (TEN) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

thymic epithelial neoplasm

MONDO:0018079

Also known as:TENThymus epithelial neoplasmThymus epithelial tumor

Find Clinical TrialsTrials

Overview

An epithelial neoplasm that affects the thymus gland. This category includes thymomas and carcinomas.

TreatmentsNo approved treatments · 4 in pipeline

Clinical Trials15 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for thymic epithelial neoplasm has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for thymic epithelial neoplasm. An additional 4 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for thymic epithelial neoplasm, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for thymic epithelial neoplasm. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

15 clinical trials registered, 5 recruiting. Interventions under study include procedural interventions, other interventions, and drug therapy. Pipeline includes 7 PHASE2, 3 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05104736](https://clinicaltrials.gov/study/NCT05104736)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:3398

GARD

Genetic and Rare Diseases Info Center

GARD:5201

Questions for Your Care Team

→Are any of the 15 active clinical trials a good fit for my situation?
→With 4 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	24	48%
Testing and diagnosis research	10	20%
Laboratory research	5	10%
Disease patterns and progression	4	8%
Clinical study results	3	6%
Patient case studies	2	4%
Other research	1	2%
New treatment approaches	1	2%

Kisho

thymic epithelial neoplasm

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

First-Line Platinum-Based Chemotherapy with Novel Systemic Agents for Unresectable or Metastatic Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis.

Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study.

thymic epithelial neoplasm

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Challenges and Controversies in the Diagnosis and Management of Thymic Epithelial Tumors from the Thymic Tumor Subcommittee of the International Association for the Study of Lung Cancer Rare Tumors Committee.

First-Line Platinum-Based Chemotherapy with Novel Systemic Agents for Unresectable or Metastatic Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis.

Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study.